

REMARKS

Claims 1-35 were previously pending. With the present amendment, Claims 31-35 have been canceled without prejudice or disclaimer, as being drawn to a non-elected invention. Claim 7 has been amended, and Claims 6, 8-9, 21 and 30 have been canceled without prejudice or disclaimer. As such, Claims 1-5, 7, 10-20, and 22-29 are pending and under consideration to the extent they read on the elected species.

In the Office Action dated August 10, 2007, the Examiner required restriction to one of the following inventions:

Group I: Claims 1-30, drawn to a method for the treatment or alleviation of depression or other affective disorders comprising administering an anti-inflammatory agent, and

Group II: Claims 31-35, drawn to a method for the identification of an anti-inflammatory agent.

Applicants elect the subject matter of Group I, presented in Claims 1-30, drawn to a method for the treatment or alleviation of depression or other affective disorders.

The Examiner has further required election of the following patentably distinct species:

- (1) a single disclosed species of a depression or other affective disorders;
- (2) a single disclosed species of an anti-inflammatory agent; and
- (3) a single disclosed species of an antidepressant.

With regard to group (1), Applicants elect a depression, specifically major depression if necessary. Claims 1-5, 7, 10-20, and 22-29 read on the elected species, and Claims 1-5, 7, 10-11, 13-20, and 22-29 are generic. With regard to group (2), Applicants elect an anti-inflammatory agent of the NSAID class, specifically ibuprofen if necessary. Claims 1-5, 7, 10-20, and 22-29 read on the elected species, and Claims 1-5, 10-20, and 22-29 are generic. With regard to group (3), Applicants elect an antidepressant of the SSRI group, specifically citalopram if necessary. Claims 1-5, 7, 10-20, and 22-29 read on the elected species, and Claims 1-5, 7, 10, 12-20, and 22-29 are generic.

Upon allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim as provided by 37 CFR § 1.141.

Should the Examiner have any questions regarding this application, the Examiner is invited to telephone the undersigned at the number provided.

Respectfully submitted,

/Milan M. Vinnola/

David R. Marsh (Reg. Attorney No. 41,408)
Milan M. Vinnola (Reg. Agent No. 45,979)

Date: September 10, 2007

ARNOLD & PORTER LLP
555 Twelfth Street, N.W.
Washington, D.C. 20004
202.942.5000 telephone
202.942.5999 facsimile